Genari Bruna, Leitune Vicente Castelo Branco, Jornada Denise Soledade, Camassola Melissa, Pohlmann Adriana Raffin, Guterres Sílvia Stanisçuaski, Samuel Susana Maria Werner, Collares Fabrício Mezzomo
Dental Materials Laboratory, School of Dentistry, Federal University of Rio Grande do Sul, Ramiro Barcelos Street, Porto Alegre, RS, 2492, Brazil.
Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Clin Oral Investig. 2017 Jan;21(1):437-446. doi: 10.1007/s00784-016-1810-7. Epub 2016 Apr 12.
The aim of this study was to produce indomethacin-loaded nanocapsules (IndOH-NCs) and evaluate the influence of their incorporation into an adhesive resin.
Indomethacin was encapsulated by the deposition of preformed polymer. IndOH-NCs were characterized by laser diffractometry, Fourier transformed infrared spectrometry, transmission electron microscopy (TEM), scanning electron microscopy, high-performance liquid chromatography (HPLC), and MTT assay. Nanocapsules (NCs) were incorporated into an adhesive in concentrations of 1, 2, 5, and 10 %. The addition was visualized by TEM and drug release was evaluated by HPLC until 120 h of immersion in simulated body fluid (SBF). Drug diffusion through dentin was tested using a Franz diffusion cell apparatus and quantified by HPLC. The degree of conversion (DC), softening in ethanol, and microtensile bond strength (μTBS) were evaluated to determine whether the nanocapsules influenced the adhesive. Data were analyzed using one-way ANOVA and Tukey's post hoc test for DC, softening in ethanol, μTBS, and cytotoxicity, and paired t test for comparison between the initial and final Knoop microhardness.
IndOH-NCs, with a spherical shape and a mean diameter of 165 nm, were incorporated into an adhesive. Indomethacin content was 7 mg drug/g powder. IndOH-NCs maintained high cell viability. At 120 h, an amount of 13.83 % of indomethacin was released, and after 7 days, 7.07 % of this drug was diffused through dentin for an adhesive containing 10 % of nanocapsules. No alteration in the DC, softening in ethanol, and μTBS resulted from NC addition.
IndOH-NCs may be incorporated into adhesive systems, without compromising properties, to add an anti-inflammatory drug controlled release for restorative procedures in deep cavities.
Here is the first step toward the goal of providing agents to act at an inflammatory process of pulp tissue through dental adhesives via encapsulation of drug.
本研究旨在制备载吲哚美辛纳米胶囊（IndOH-NCs），并评估其掺入黏结树脂后的影响。
通过预成型聚合物沉积法包封吲哚美辛。采用激光衍射法、傅里叶变换红外光谱法、透射电子显微镜（TEM）、扫描电子显微镜、高效液相色谱（HPLC）和MTT法对IndOH-NCs进行表征。将纳米胶囊（NCs）以1%、2%、5%和10%的浓度掺入黏结剂中。通过TEM观察添加情况，并通过HPLC评估药物释放，直至在模拟体液（SBF）中浸泡120小时。使用Franz扩散池装置测试药物通过牙本质的扩散情况，并通过HPLC进行定量。评估转化率（DC）、在乙醇中的软化程度和微拉伸粘结强度（μTBS），以确定纳米胶囊是否影响黏结剂。使用单因素方差分析和Tukey事后检验分析DC、在乙醇中的软化程度、μTBS和细胞毒性数据，使用配对t检验比较初始和最终努氏显微硬度。
IndOH-NCs呈球形，平均直径为165nm，已掺入黏结剂中。吲哚美辛含量为7mg药物/g粉末。IndOH-NCs保持了较高的细胞活力。在120小时时，释放了13.83%的吲哚美辛，7天后，对于含有10%纳米胶囊的黏结剂，该药物有7.07%扩散通过牙本质。添加NCs未导致DC、在乙醇中的软化程度和μTBS发生改变。
IndOH-NCs可掺入黏结系统中，而不影响其性能，为深龋修复程序添加抗炎药物控释功能。
这是朝着通过药物包封，利用牙科黏结剂向牙髓组织炎症过程提供作用药物这一目标迈出的第一步。
